RNA Clinical Trials Videos

  1. Who's In Charge? How To Ensure Effective Trial Oversight, Leadership 3/19/2025

    Gain valuable insights into the role of sponsor-side Clinical Operations leadership, the risks of over-relying on CROs, and key strategies for fostering collaboration between sponsors and partners.

  2. Q&A On LNP Cell-Specific Delivery 11/28/2022

    In this video, Russell Johnson, VP Formulation Research for RVAC Medicines, and Aalok Shah, Director of Formulation & Drug Delivery for Strand Therapeutics, outline several examples of foundational research that could provide insights into how we attain more specific cellular uptake of LNPs.

  3. Precision ADVANCE: Unravelling The Complexity Of CGTx Development 10/12/2021

    Need help unravelling the complexity of CGTx development? Four experts explain Precision ADVANCE’s unique approach. Spend 50 seconds with Anshul Mangal, Deb Phippard, Megan Liles, and Philip Cyr.

  4. A Snapshot Of The RNA Industry & Its Regulatory Progress 5/10/2024

    The experts on this Advancing RNA Live panel share their takeaways from several audience poll questions revealing which RNA molecules are getting the lion’s share of attention/development today.

  5. Accelerating Development In Novel & Advanced Oncology Therapies 6/15/2023

    Hear from a panel of industry experts on dissecting the shift in early-phase oncology design, focusing on Bayesian Data.

  6. Development And Regulatory Strategy For US And China 9/22/2022

    This webinar discusses the expansion of International Market for Ensartini and RNAi Therapeutics in Oncology, from Skin Cancers to Liver Cancers.

  7. Michelangelo Meets mRNA | ARW on RNA Ep04 5/4/2023

    Hosted by Cell & Gene Collaborative's Director Anna Rose Welch, ARW on RNA puts a creative spin on the emerging mRNA + RNA therapeutics industry. Here, in Episode 4, Welch explores the parallels that exist between the oft-overlooked history of Michelangelo's David and the mRNA therapeutics sector's own R&D history, as well as where the mRNA space hopes to move in the future.

  8. Oligonucleotide Opportunities in DMD with PepGen's James McArthur, Ph.D. 7/25/2022

    Among the more prevalent genetic conditions, Duchenne muscular dystrophy affects an estimated one in 3,500 male births worldwide. It's caused by mutations of the DMD gene, which regulates the production of a protein called dystrophin. Approved DMD treatments haven't demonstrated strong clinical outcomes, but James McArthur, Ph.D. and his team at PepGen are seeking to change that with a pipeline of disease-modifying peptide-conjugated oligonucleotide candidates derived from the company's Enhanced Delivery Oligonucleotide platform. The Business of Biotech caught up with Dr. McArthur at PepGen's Cambridge headquarters to learn more.

  9. Goldilocks & The 3…CQAs? Finding "Just Right" With LNP Optimization 12/4/2024

    Three LNP experts from Sanofi, Hopewell Therapeutics, and BioNTech collectively discuss how far we’ve come in understanding the structure of our LNPs while also shedding light on the variables that have the greatest potential of causing shifts in our products’ structure/function.

  10. The Scientific Underpinnings Of mRNA/LNPs 11/28/2022

    In this video, Russell Johnson, VP Formulation Research for RVAC Medicines, and Aalok Shah, Director of Formulation & Drug Delivery, Strand Therapeutics, share their thoughts on the scientific-research and CMC-related reasons that have made the lipid nanoparticle the “darling” of the delivery world for mRNA/RNA products today.